Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 3
1(20.0%)
5Total
N/A(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05639257Not ApplicableUnknown

Treatment of Myotonia - Lamotrigine Versus Namuscla

Role: lead

NCT01939561Phase 3Completed

Lamotrigine as Treatment of Myotonia

Role: lead

NCT02159963Not ApplicableCompleted

High Intensity Training in Patients With Facioscapulohumeral Muscular Dystrophy

Role: lead

NCT02161835Not ApplicableCompleted

Relations Between Myotonia and Fitness

Role: lead

NCT02159612Completed

1 Year MRI Followup in Facioscapulohumeral Muscular Dystrophy

Role: lead

NCT01618331Not ApplicableCompleted

Protein Supplementation and Exercise in Patients With FSH Muscular Dystrophy- a Randomized Placebo Controlled Study

Role: lead

All 6 trials loaded